Related Experiment Video
Updated: Aug 4, 2026

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model
Published on: October 31, 2012
Different embryo-fetal toxicity effects for three VLA-4 antagonists
1Department of Drug Safety Evaluation, Aventis Inc., Bridgewater, New Jersey 08807, USA. Frances.Crofts@aventis.com
Background:
VLA-4 (Very late antigen 4, integrin alpha4beta1) plays an important role in cell-cell interactions that are critical for development. Homozygous null knockouts of the alpha4 subunit of VLA-4 or VCAM-1 (cell surface ligand to VLA-4) in mice result in abnormal placental and cardiac development and embryo lethality. Objectives of the current study were to assess and compare the teratogenic potential of three VLA-4 antagonists.
Methods:
IVL745, HMR1031, and IVL984 were each evaluated by the subcutaneous route in standard embryo-fetal developmental toxicity studies in rats and rabbits. IVL984 was also evaluated in mice. Fetuses were examined externally, viscerally, and skeletally.
Results:
IVL745 did not cause significant maternal or fetal effects at doses up to 100 or 250 mg/kg/day in rats or rabbits, respectively. HMR1031 treatment resulted in marked maternal toxicity and slight fetal toxicity at the highest tested doses of 200 and 75 mg/kg/day in rats and rabbits, respectively. HMR1031 embryo-fetal effects consisted of slightly lower body weight and crown-rump length in rats and minor sternebral defects in rabbits. IVL984 treatment resulted in minimal maternal effects at doses up to 40, 15, and 100 mg/kg/day in rats, rabbits, and mice, respectively (excluding abortions in rabbits). However, marked developmental effects were observed at the lowest tested IVL984 doses, 1, 0.2, and 3 mg/kg/day in rats, rabbits, and mice, respectively. IVL984 embryo-fetal effects consisted of increased total post-implantation loss due to early resorptions and high incidences of cardiac malformations and skeletal malformations and/or variations. Notably, spiral septal defects were observed in up to 76% of rat fetuses and up to 58% of rabbit fetuses.
Conclusions:
Dramatic differences in teratogenic potential were observed: IVL745 was not teratogenic, HMR1031 caused slight embryo-fetal effects at maternally-toxic doses, and IVL984 was a potent teratogen at doses where direct maternal toxicity was limited to abortions in rabbits. Prominent effects of IVL984 included embryo lethality and cardiac malformations including spiral septal defects in three species.
Insights
The VLA-4 antagonist IVL984 demonstrated potent teratogenicity, causing embryo lethality and cardiac malformations, including spiral septal defects, in multiple species. In contrast, IVL745 showed no teratogenic effects, and HMR1031 caused only slight embryo-fetal effects at maternally toxic doses.
Area of Science:
- Developmental toxicology
- Pharmacology
- Immunology
Background:
- Very late antigen 4 (VLA-4) is crucial for cell-cell interactions during development.
- Genetic deficiencies in VLA-4 or its ligand VCAM-1 lead to embryonic lethality due to abnormal development.
- Understanding VLA-4 antagonist teratogenicity is vital for drug safety.
Purpose of the Study:
- To evaluate and compare the teratogenic potential of three VLA-4 antagonists: IVL745, HMR1031, and IVL984.
- To identify dose-dependent effects and specific malformations induced by these compounds.
- To assess the safety profile of VLA-4 antagonists during embryonic development.
Main Methods:
- Standard embryo-fetal developmental toxicity studies were conducted in rats and rabbits via subcutaneous administration.
- IVL984 was also tested in mice.
- Fetuses underwent external, visceral, and skeletal examinations to identify developmental abnormalities.
Main Results:
- IVL745 exhibited no significant maternal or fetal toxicity at tested doses.
- HMR1031 caused maternal toxicity and slight fetal effects (e.g., reduced body weight, sternebral defects) at high doses.
- IVL984 was a potent teratogen, inducing embryo lethality, cardiac malformations (including spiral septal defects), and skeletal defects at low doses, with minimal maternal toxicity except for abortions in rabbits.
Conclusions:
- IVL745 is not teratogenic.
- HMR1031 demonstrates mild embryo-fetal toxicity at maternally toxic doses.
- IVL984 is a potent teratogen, causing significant developmental abnormalities, including cardiac malformations and embryo lethality, across multiple species at non-maternally toxic doses.
More Related Videos
12:02Using Tg(Vtg1:mcherry) Zebrafish Embryos to Test the Estrogenic Effects of Endocrine Disrupting Compounds
Published on: August 8, 2020
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Teratogenicity
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions